RP913

RP913 is a proteolysis-targeting chimera (PROTAC) designed to induce the degradation of the KRAS G12D mutant protein. Developed by Risen Shanghai Medical Technology (Risen Pharma), it is currently in the IND-enabling stage for the treatment of various cancers driven by the KRAS G12D mutation. KRAS G12D is a common oncogenic driver in several solid tumors, including pancreatic, colorectal, and non-small cell lung cancers. By utilizing the PROTAC modality, RP913 aims to overcome the limitations of traditional small-molecule inhibitors by facilitating the ubiquitination and subsequent proteasomal degradation of the target protein, potentially offering more potent and durable therapeutic effects.